Ads
related to: malignant adenocarcinoma pancreas pathology outlines- FDA-Approved Treatment
Regimen For Somatostatin Receptor-
Positive GEP-NETs. HCPs Resources.
- Find A Treatment Center
Use This Treatment Site Locator
To Find Nearest Treatment Center.
- Learn About GEP-NETs
HCPs, Get Info About The Condition.
Visit a Product Site About GEP-NETs
- Patient Resources
View Resources For Your Patients.
Find Helpful Support Information.
- FDA-Approved Treatment
Search results
Results From The WOW.Com Content Network
The most common, pancreatic adenocarcinoma, accounts for about 90% of cases, [11] and the term "pancreatic cancer" is sometimes used to refer only to that type. [10] These adenocarcinomas start within the part of the pancreas that makes digestive enzymes . [ 10 ]
Papillae vs pseudopapillae: True papillae are outgrowths of epithelium, surrounding fibrovascular cores of stroma and at least one blood vessel. In contrast, pseudopapillae (such as in solid pseudopapillary tumours) are nests of proliferating cells that eventually grow to become almost back-to-back, with cells in the centers of nests disintegrating, leaving rims of cells lining the periphery ...
Adenocarcinoma is the malignant counterpart to adenoma, which is the benign form of such tumors. Sometimes adenomas transform into adenocarcinomas, but most do not. Well- differentiated adenocarcinomas tend to resemble the glandular tissue that they are derived from, while poorly differentiated adenocarcinomas may not.
In contrast to some of the other cyst-forming tumors of the pancreas (such as the intraductal papillary mucinous neoplasm and the pancreatic mucinous cystadenoma), serous cystic neoplasms are almost always entirely benign. There are some exceptions; rare case reports have described isolated malignant serous cystadenocarcinomas. [3]
A pancreatic tumor is an abnormal growth in the pancreas. [1] In adults, almost 90% are pancreatic cancer and a few are benign. [1] Pancreatic tumors are rare in children. [1] Classification is based on cellular differentiation (ductal, acinar, neuroendocrine, other) and gross appearance (intraductal, cystic, solid). [1]
Gross pathology: Main duct, branch duct, and mixed duct lesions, which determines surgical management. Main duct lesion is the segmental or diffuse dilatation of main pancreatic duct greater than 5 mm without other causes of obstruction. Meanwhile, branch duct lesion is the pancreatic cyst more than 5 mm that communicates with the main duct.